Author:
Kleijnen Sarah,Leonardo Alves Teresa,Meijboom Kim,Lipska Iga,De Boer Anthonius,Leufkens Hubertus G.,Goettsch Wim G.
Abstract
Abstract
Purpose
The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures.
Methods
Comparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013.
Results
Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a relevant endpoint to determine the relative effectiveness of new cancer drugs, QoL data were included in only 54% of the 79 reports and their impact on the recommendations was limited.
Conclusions
Whilst national guidelines recognize the relevance of QoL to determine the relative effectiveness of new anti-cancer drugs, this is not well-reflected in current assessments. Developing and implementing into REAs specific evidence requirements for QoL data would improve the use of this patient-centred outcome in future reimbursement and pricing decisions.
Funder
Zorginstituut Nederland
Utrecht Institute for Pharmaceutical Sciences
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference29 articles.
1. Cherny, N. I., Sullivan, R., Dafni, U., et al. (2015). A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 26(8), 1547–1573.
2. Wilson, M. K., Collyar, D., Chingos, D. T., et al. (2015). Outcomes and endpoints in cancer trials: Bridging the divide. Lancet Oncology, 16, e43–e52.
3. Wilson, M. K., Karakasis, K., & Oza, A. M. (2015). Outcomes and endpoints in trial of cancer treatment: The past, present, and future. Lancet Oncology, 16, e32–e42.
4. Jacobsen, P. B., Davis, K., & Cella, D. (2002). Assessing quality of life in research and clinical practice. Retrieved November 8, 2015, from http://www.cancernetwork.com/. UBM Medica Network.
5. Lipscomb, J., Gotay, C. C., & Snyder, C. F. (2007). Patient-reported outcomes in cancer: A review of recent research and policy initiatives. CA Cancer Journal for Clinicians, 57(5), 278–300.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献